Skip to Content

Gemtuzumab Ozogamicin Injection

Last Updated: October 19, 2010
Status: Discontinued

Products Affected - Description

Mylotarg, Pfizer
5 mg vial, lyophilized powder for injection (NDC 00008-4510-01)

Reason for the Shortage

Pfizer is withdrawing Mylotarg from the market because the post-approval study did not show survival benefit and increased toxicity was seen over standard chemotherapy for patients with acute myeloid leukemia.

Estimated Resupply Dates

Pfizer has withdrawn Mylotarg from the US market. No new patients should be started on Mylotarg at this time. Patients currently on Mylotarg should consult their healthcare professional and may continue therapy if clinically appropriate.

Related Shortages

Updated

October 19, 2010, University of Utah, Drug Information Service. Copyright 2010, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide